Christian Buske, MD, on the Influence of CAR T-Cells Being Presented at ASH

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

In an interview with CancerNetwork®,Christian Buske, MD, of the University Ulm in Germany, spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for patients with lymphoma moving forward.

Transcription:

I think CAR Ts are really amazing. So, we know they have an already established role in diffuse large B-cell lymphoma (DLBCL), but soon we will have data showing us whether CAR Ts can go into second-line treatment. And here, at this year's ASH, there are already approaches using CAR Ts in first-line DLBCL in high-risk patients who are PET-positive after 2 cycles of standard R-CHOP, have high IPI, and have a certain high-risk molecular profile.

We have very interesting data at ASH, which will show us how efficient CAR Ts are in relapsed mantle cell lymphoma. So, I think CAR T is for sure (interesting) and the second are the bispecific antibodies, targeting CD20 and CD38 that we will hear at ASH. A lot of early data about promising data demonstrating that these bispecific antibodies have a high activity… I would probably say these two things.